JP2009542716A5 - - Google Patents

Download PDF

Info

Publication number
JP2009542716A5
JP2009542716A5 JP2009518602A JP2009518602A JP2009542716A5 JP 2009542716 A5 JP2009542716 A5 JP 2009542716A5 JP 2009518602 A JP2009518602 A JP 2009518602A JP 2009518602 A JP2009518602 A JP 2009518602A JP 2009542716 A5 JP2009542716 A5 JP 2009542716A5
Authority
JP
Japan
Prior art keywords
propyl
medicament according
amino
alkyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009518602A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009542716A (ja
JP5599610B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/072671 external-priority patent/WO2008005937A2/en
Publication of JP2009542716A publication Critical patent/JP2009542716A/ja
Publication of JP2009542716A5 publication Critical patent/JP2009542716A5/ja
Application granted granted Critical
Publication of JP5599610B2 publication Critical patent/JP5599610B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009518602A 2006-06-30 2007-07-02 Ｈｓｐ９０の阻害による神経変性疾患の処置 Expired - Fee Related JP5599610B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80642706P 2006-06-30 2006-06-30
US60/806,427 2006-06-30
PCT/US2007/072671 WO2008005937A2 (en) 2006-06-30 2007-07-02 Treatment of neurodegenerative diseases through inhibiton of hsp90

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013058040A Division JP5824698B2 (ja) 2006-06-30 2013-03-21 Ｈｓｐ９０の阻害による神経変性疾患の処置

Publications (3)

Publication Number Publication Date
JP2009542716A JP2009542716A (ja) 2009-12-03
JP2009542716A5 true JP2009542716A5 (enExample) 2010-09-02
JP5599610B2 JP5599610B2 (ja) 2014-10-01

Family

ID=38895418

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2009518602A Expired - Fee Related JP5599610B2 (ja) 2006-06-30 2007-07-02 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2013058040A Expired - Fee Related JP5824698B2 (ja) 2006-06-30 2013-03-21 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2015174609A Pending JP2016028063A (ja) 2006-06-30 2015-09-04 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2017110721A Expired - Fee Related JP6427227B2 (ja) 2006-06-30 2017-06-05 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2018202024A Expired - Fee Related JP6585266B2 (ja) 2006-06-30 2018-10-26 Ｈｓｐ９０の阻害による神経変性疾患の処置

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2013058040A Expired - Fee Related JP5824698B2 (ja) 2006-06-30 2013-03-21 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2015174609A Pending JP2016028063A (ja) 2006-06-30 2015-09-04 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2017110721A Expired - Fee Related JP6427227B2 (ja) 2006-06-30 2017-06-05 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2018202024A Expired - Fee Related JP6585266B2 (ja) 2006-06-30 2018-10-26 Ｈｓｐ９０の阻害による神経変性疾患の処置

Country Status (8)

Country Link
US (5) US10336757B2 (enExample)
EP (2) EP2034839B1 (enExample)
JP (5) JP5599610B2 (enExample)
AU (1) AU2007269144B2 (enExample)
CA (1) CA2656202C (enExample)
DK (1) DK2034839T3 (enExample)
ES (1) ES2645095T3 (enExample)
WO (1) WO2008005937A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834181B2 (en) * 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
AU2007249194B2 (en) * 2006-05-12 2012-11-22 Myrexis, Inc. Therapeutic compounds and their use in cancer
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
EA019103B1 (ru) 2007-03-20 2014-01-30 Кьюрис, Инк. Конденсированный аминопиридин в качестве ингибиторов hsp90
AU2008322503A1 (en) * 2007-11-14 2009-05-22 Myrexis, Inc. Therapeutic compounds and their use in treating diseases and disorders
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
JP5616336B2 (ja) 2008-06-26 2014-10-29 オルファザイム エーピーエスＯｒｐｈａｚｙｍｅ Ａｐｓ 酵素活性の調節因子としてのＨｓｐ７０の使用
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
AU2013204109B2 (en) * 2009-10-07 2016-05-05 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
PT2486039T (pt) 2009-10-07 2016-09-06 Sloan Kettering Inst For Cancer Res Derivados de purina úteis como inibidores de hsp90
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
MX354215B (es) 2011-04-05 2018-02-19 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
AU2012240077C1 (en) 2011-04-05 2017-08-10 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
ES2624982T3 (es) 2011-07-08 2017-07-18 Sloan-Kettering Institute For Cancer Research Usos de inhibidores etiquetados HSP90
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
EP2879675B1 (en) 2012-08-06 2019-11-13 Duke University Compounds and methods for targeting hsp90
US9156831B2 (en) 2013-01-23 2015-10-13 Astrazeneca Ab Chemical compounds
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
KR102319582B1 (ko) 2013-08-16 2021-11-04 메모리얼 슬로안 케터링 캔서 센터 선택적 ｇｒｐ９４ 저해제 및 이의 용도
EP3738594A1 (en) 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Targeted therapeutics having an hsp90 ligand as binding moiety
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
MX2016008418A (es) 2013-12-23 2017-01-11 Memorial Sloan Kettering Cancer Center Metodos y reactivos para el radiomarcaje.
EP3099332A4 (en) 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
JP6576942B6 (ja) 2014-03-03 2019-11-27 マドリガル ファーマシューティカルズ インコーポレイテッド 標的治療薬
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
EP3194975A4 (en) * 2014-09-17 2018-05-02 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
JP7132848B2 (ja) 2015-10-05 2022-09-07 メモリアル スローン ケタリング キャンサー センター 癌の治療のための合理的併用療法
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
WO2017184956A1 (en) 2016-04-22 2017-10-26 Duke University Compounds and methods for targeting hsp90
ES2831764T3 (es) 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
WO2018200534A1 (en) * 2017-04-24 2018-11-01 Samus Therapeutics, Inc. Hsp90 inhibitor oral formulations and related methods
US11491145B2 (en) 2017-06-20 2022-11-08 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics
US11377447B2 (en) 2017-06-20 2022-07-05 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
CN111683658A (zh) * 2017-06-23 2020-09-18 萨缪斯治疗股份有限公司 用于创伤性脑损伤及其后遗症的多蛋白复合物抑制剂疗法
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE460423T1 (de) 1997-05-14 2010-03-15 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
AU769235B2 (en) 1999-04-09 2004-01-22 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
US7439359B2 (en) 2000-11-02 2008-10-21 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
US20040235813A1 (en) * 2001-05-03 2004-11-25 Erich Wanker Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
EP1440072A4 (en) 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
WO2003041643A2 (en) 2001-11-09 2003-05-22 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
NZ535592A (en) 2002-02-28 2006-07-28 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents
US7592143B2 (en) * 2003-04-18 2009-09-22 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
US20070178537A1 (en) 2003-06-30 2007-08-02 Sloan-Kettering Institute For Cancer Research Assays for detection of bioactive compounds that interact with heat shock protein 90
NZ546611A (en) 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) * 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
JP4377942B2 (ja) * 2005-02-25 2009-12-02 セレネックス， インコーポレイテッド テトラヒドロインドロン及びテトラヒドロインダゾロン誘導体
WO2006130469A1 (en) * 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules
WO2007117466A2 (en) 2006-03-31 2007-10-18 Massachusetts Institute Of Technology Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
AU2007249194B2 (en) * 2006-05-12 2012-11-22 Myrexis, Inc. Therapeutic compounds and their use in cancer
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
WO2008013985A2 (en) 2006-07-27 2008-01-31 University Of Florida Use of heat shock activators for tissue regeneration
SG174772A1 (en) * 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
GB0622084D0 (en) 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
WO2008070472A2 (en) 2006-11-27 2008-06-12 University Of Maryland, Baltimore Use of plasma hsp90 related to malignancy
EA019103B1 (ru) * 2007-03-20 2014-01-30 Кьюрис, Инк. Конденсированный аминопиридин в качестве ингибиторов hsp90
WO2008115262A2 (en) * 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
EP2183221A1 (en) 2007-07-12 2010-05-12 Crystax Pharmaceuticals S.L. New compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
AU2008322503A1 (en) 2007-11-14 2009-05-22 Myrexis, Inc. Therapeutic compounds and their use in treating diseases and disorders
PT2486039T (pt) 2009-10-07 2016-09-06 Sloan Kettering Inst For Cancer Res Derivados de purina úteis como inibidores de hsp90
MX354215B (es) 2011-04-05 2018-02-19 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
AU2012240077C1 (en) 2011-04-05 2017-08-10 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
KR102319582B1 (ko) 2013-08-16 2021-11-04 메모리얼 슬로안 케터링 캔서 센터 선택적 ｇｒｐ９４ 저해제 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2017511360A5 (enExample)
MY136034A (en) New medicaments for the treatment of chronic obstructive pulmonary disease
JP2009538897A5 (enExample)
JP2005510473A5 (enExample)
EP1857457A3 (en) Benzimidazole derivative and its use as AII receptor antagonist
JP2020502092A5 (enExample)
RU2006134020A (ru) Конденсированные производные пиразола
CA3095233A1 (en) 4-(3-amino-6-fluoro-1h-indazol-5-yl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dic arbonitrile compounds for treating hyperproliferative disorders
JP2016507502A5 (enExample)
JP2010501478A5 (enExample)
JP2011506566A5 (enExample)
JP2016539138A5 (enExample)
EP4327877A3 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
JP2018531987A5 (enExample)
WO2005111002A3 (de) Substituierte cycloalkylderivate zur behandlung von atemswegerkrankungen
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
JP2016525104A5 (enExample)
JP2015522592A5 (enExample)
JP2011518168A5 (enExample)
JP2007538031A5 (enExample)
JP2016520636A5 (enExample)
JP2017524674A5 (enExample)
JP2016523830A5 (enExample)
JP2012511558A5 (enExample)
JP5430552B2 (ja) ベンゾ［ａ］フェノキサチン化合物を有効成分として含有する原虫疾患予防又は治療用医薬組成物